Previous 10 | Next 10 |
Deals and Financings According to Bloomberg, I-Mab BioPharma (IMAB) of Shanghai is shopping its CD-47 immunoncology candidate to various global biopharmas with hopes of forming a $2 billion collaboration (see story ). I-Mab believes TJC4 is a potential global best-in-class CD47 because it b...
- Companies to utilize proprietary platforms to discover, develop, and manufacture potential therapeutic antibodies to combat ongoing COVID-19 pandemic - SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass. and BEIJING, China and MOUNTAIN VIEW, Calif., April 29, 2020 (GLOBE NEWSWIRE...
Adaptimmune (NASDAQ: ADAP ) initiated with Neutral rating and $3 (17% downside risk) price target at Mizuho Securities. More news on: Adaptimmune Therapeutics plc, Autolus Therapeutics plc, Atreca, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
The biotechnology industry's chock-full of stocks that could quickly skyrocket overnight and make you filthy rich in the process. All three of these clinical-stage biotechs are relatively small at the moment, but they have potential blockbuster drugs in development that could send their stock pr...
One of the trends in the first quarter of 2020 has been the significant underperformance of small-cap equities as a market segment amid the extreme levels of volatility. For context, the iShares Russell 2000 ETF ( IWM ) is down about 25% compared to a 13% decline in the S&P 500 Index ( S...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
MOUNTAIN VIEW, Calif., April 03, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a panel di...
Image source: The Motley Fool. IGM Biosciences Inc (NASDAQ: IGMS) Q4 2019 Earnings Call Mar 26, 2020 , 4:30 p.m. ET Operator Continue reading
IGM Biosciences, Inc. (IGMS) Q4 2019 Earnings Conference Call March 26, 2020, 04:30 PM ET Company Participants Fred Schwarzer - CEO Misbah Tahir - CFO Bruce Keyt - Chief Scientific Officer Dan Chen - Chief Medical Officer Conference Call Participants Stephen Willey - Stif...
IGM Biosciences (NASDAQ: IGMS ): Q4 GAAP EPS of -$0.49 misses by $0.06 . More news on: IGM Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
2024-05-31 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 12:15:03 ET RBC Capital analyst issues UNDERPERFORM recommendation for IGMS on May 24, 2024 10:00AM ET. The previous analyst recommendation was Underperform. IGMS was trading at $10.01 at issue of the analyst recommendation. The overall analyst consensus : BUY...